Ornithine translocase deficiency
Ornithine translocase deficiency is a rare metabolic disorder characterized by an inability of the body to transport the amino acid ornithine. This condition is also known as Hyperornithinemia-Hyperammonemia-Homocitrullinuria (HHH) syndrome. It is a type of urea cycle disorder, which affects the body's ability to get rid of ammonia, a toxic byproduct of protein metabolism.
Symptoms[edit | edit source]
The symptoms of Ornithine translocase deficiency can vary widely, ranging from mild to severe. They may include neurological problems, such as developmental delay, intellectual disability, and seizures; gastrointestinal issues, such as vomiting, diarrhea, and failure to thrive; and other symptoms, such as liver disease and hair loss.
Causes[edit | edit source]
Ornithine translocase deficiency is caused by mutations in the SLC25A15 gene. This gene provides instructions for making a protein that is found in the mitochondria, the energy-producing centers of cells. The protein, called ornithine translocase, is responsible for transporting ornithine across the mitochondrial membrane.
Diagnosis[edit | edit source]
Diagnosis of Ornithine translocase deficiency is typically made through genetic testing, which can identify mutations in the SLC25A15 gene. Other tests, such as blood tests and urine tests, may also be used to measure levels of ammonia and other substances in the body.
Treatment[edit | edit source]
Treatment for Ornithine translocase deficiency typically involves a low-protein diet to reduce the amount of ammonia produced by the body. Medications may also be used to help remove ammonia from the body. In severe cases, liver transplantation may be considered.
Prognosis[edit | edit source]
The prognosis for individuals with Ornithine translocase deficiency varies depending on the severity of the condition and the effectiveness of treatment. With early diagnosis and appropriate treatment, many individuals with this condition can lead relatively normal lives.
See also[edit | edit source]
This metabolic pathology-related article is a stub. You can help WikiMD by expanding it.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD